Australian public assessment for Rituximab

The sponsor has also applied to make changes to the PI for both the MabThera SC 1400 mg formulation and MabThera IV formulation (dose calculated on body surface area) to increase the dosage frequency of the dose in maintenance treatment of non-Hodgkin’s lymphoma (NHL) from 3 monthly to 2 monthly, in patients with previously untreated follicular lymphoma who have responded to induction treatment. ................
................